Selected References:
- Cohen LS, et al. 2023. Reproductive safety of lurasidone and quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J Womens Health (Larchmt). 32(4):452-462.
- Cruz MP. 2011. Lurasidone HCl (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia. P & T : a peer-reviewed journal for formulary management, 36(8):489–492.
- Damkier, P & Videbech, P. 2018. The safety of second-generation antipsychotics during pregnancy: A clinically focused review. CNS Drugs 32:351–366.
- 2011. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Available at http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.
- Greenberg, WM & Citrome, L. 2017. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet 56:493–503.
- Kantrowitz JT, Citrome L. 2012. Lurasidone for schizophrenia: what’s different? Expert Rev Neurother. 12(3):265-73.
- Keightley P, et al. 2020. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry. 54:1035–1036.
- Montiel C, et al. 2022 Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol. 30(2):249-252.
- Sumitomo Pharma America, Inc. (Last updated: July 21, 2023). Latuda drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8.
- Terrana, N, et al. 2015. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 35(5):559–565.
